ArticleFrontiers in bioengineering and biotechnology2026
A perspective and demonstration of an approach to screening synthetic nucleic acid orders containing short nucleic acid sequences.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Compounding asymmetries in nucleic acid synthesis screening: policy pathways for strengthening global biosecurity governance.Frontiers in bioengineering and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Screening of nucleic acid synthesis orders is expanding to include short, single-stranded DNA orders in efforts to ensure potentially harmful genes and genomes cannot be synthesized by illegitimate or irresponsible customers. Short sequence fragments are not as information rich as gene sequences, typically require assembly to be functional, and are much cheaper to produce than genes. Thus, here we provide the perspective that the screening of sequence fragments requires a different approach than sequence-by-sequence screening by considering the context of other fragments in the order or across orders. Additional and alternative metrics should be included while screening fragments, such as fraction of the gene/genome covered and evidence of potential use for assembly to enable efficient and accurate biosecurity screening. We further demonstrate two existing biosecurity tools, UltraQUICK and Aclid that provide outputs for better understanding the threat of orders containing fragments. This perspective provides a foundation for how short DNA fragments, including oligo pools, should be screened and leaves the reader with considerations for overall risk assessments of such orders based on the functional and taxonomic characteristics of the order.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.